GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV).

RSV is a common respiratory virus that can lead to serious negative clinical outcomes, such as lower respiratory tract disease (LRTD) and pneumonia in older adults.